BIOGEN (DENMARK) A/S: Financial statements 2025
CVR: 21682977
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
BIOGEN (DENMARK) A/S (CVR 21682977) has filed annual accounts for 2025. In 2025, the company reported revenue of DKK 178,728,185 and a net result of DKK 5,563,672 compared with DKK 7,526,703 the year before. That is a decrease of 23.6% compared with the year before. The profit margin was 3.1%. Equity in the 2025 report amounted to DKK 151,886,117. The solvency ratio was 81.1%. The company had 20 employees in the financial year.
- Revenue
- DKK 178,728,185
- Gross Profit
- DKK 34,062,002
- Profit/Loss
- DKK 5,563,672
- Equity
- DKK 151,886,117
- Total Assets
- DKK 187,240,222
- Employees
- 20
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | 178.7 mio. | 34.1 mio. | 5.6 mio. | 151.9 mio. | 20 |
| 2024 | 234 mio. | 32.9 mio. | 7.5 mio. | 146.3 mio. | 22 |
| 2023 | 259.6 mio. | 44.2 mio. | 8.3 mio. | 138.8 mio. | 24 |
| 2022 | 307.5 mio. | 47 mio. | 8.4 mio. | 130.5 mio. | 24 |
| 2021 | 259.7 mio. | 45.9 mio. | 7.6 mio. | 122 mio. | 22 |
Official annual report
How creditworthy is BIOGEN (DENMARK) A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
BIOGEN (DENMARK) A/S has won the tender "Rammeaftale om køb af Spinraza® (nusinersen)" issued by Amgros I/S worth 80,000,000 DKK.
BIOGEN (DENMARK) A/S has published its annual report for 2024. Revenue came to DKK 234,002,651, and the net result was DKK 7,526,703.
BIOGEN (DENMARK) A/S has won the tender "Rammeaftale om køb af Qalsody (tofersen)" issued by Amgros I/S worth 39,050,000 DKK.
BIOGEN (DENMARK) A/S has won the tender "Rammeaftale om køb af Skyclarys (omaveloxolon)" issued by Amgros I/S worth 41,500,000 DKK.
BIOGEN (DENMARK) A/S has won the tender "Amgros 2025 1.160.a" issued by Amgros I/S worth 456,000,000 DKK.
BIOGEN (DENMARK) A/S has won the tender "Amgros 2025 1.161.b" issued by Amgros I/S worth 472,500,000 DKK.
BIOGEN (DENMARK) A/S has won the tender "Amgros 2025 1.142.b" issued by Amgros I/S worth 391,000,000 DKK.
About BIOGEN (DENMARK) A/S
BIOGEN (DENMARK) A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 1999. The company is registered under the industry Engroshandel med læge- og hospitalsartikler. The company was previously named BIOGEN IDEC (DENMARK) A/S. The management consists of Erik Magnus Bodin. The board consists of Neil Raymond Sisak (chair), Allan Frank Fischer Petersen, Erik Magnus Bodin and Sergio Ferreira da Silva Teixeira. The company is owned by Biogen Netherlands B.V.. The company has 13 employees (2026). In 2025, the company reported revenue of DKK 178,728,185 and a net result of DKK 5,563,672 compared with DKK 7,526,703 the year before. Equity in the 2025 report amounted to DKK 151,886,117.